Breast Cancer – Risk of Recurrence
Oncotype DX® Breast Cancer Assay
Test available from: Your local cancer treatment center in Ireland
The Oncotype DX® Breast Cancer Assay can help physicians and patients decide on the best course of treatment. For invasive breast cancer, the Oncotype DX Breast Cancer Assay predicts chemotherapy benefit and the likelihood of distant breast cancer recurrence. The Oncotype DX Breast Cancer Assay for DCIS patients predicts the risk of local recurrence. Even when traditional measures seem conclusive, Oncotype DX Recurrence Score can lead to a different approach.
The Oncotype DX® Breast Cancer Assays provide physicians and their patients with critical information needed to help guide treatment decision making in women with ductal carcinoma in situ (DCIS) or invasive carcinoma. The Oncotype DX® Breast Cancer Assay can predict the potential benefit of chemotherapy and likelihood of distant breast cancer recurrence in women with node negative or node positive, ER-positive, HER2-negative invasive breast cancer. The Oncotype DX® Breast Cancer Assay for DCIS patients quantifies the 10-year risk of local recurrence (DCIS or invasive carcinoma) in women with ductal carcinoma in situ treated by local excision, with or without tamoxifen. These assays are designed to support treatment planning and can lead to a more personalized treatment approach.
Article source: Oncotypeiq
Test available from:
Agendia.com (through your physician)
What is MammaPrint?
Agendia’s MammaPrint is a test which determines how aggressive a breast cancer tumour is. The MammaPrint result will enable your physician to determine what would be the best kind of treatment for you following your operation.
The result of a MammaPrint is very clear: there is either a low risk of metastasis (‘good prognosis’) or a high risk of metastasis (‘bad prognosis’).
Test available from:
Nanostring Technologies (through your physician)
About the Prosigna™ Breast Cancer Prognostic Gene Signature Assay
Prosigna provides a risk category and numerical score for assessment of the risk of distant recurrence of disease at 10 years in postmenopausal women with node-negative (Stage I or II) or node-positive (Stage II), hormone receptor-positive (HR+) breast cancer.
Based on the PAM50 gene signature initially discovered by Charles Perou, Ph.D. and colleagues, the Prosigna Assay is an in vitro diagnostic tool that utilizes gene expression data weighted together with clinical variables to generate a risk category and numerical score, to assess a patient’s risk of distant recurrence. The Prosigna Assay measures gene expression levels of RNA extracted from formalin-fixed paraffin-embedded (FFPE) breast tumor tissue.
The Prosigna Assay requires minimal hands-on time and runs on NanoString’s proprietary nCounter Dx Analysis System, which offers a reproducible and cost-effective way to profile many genes simultaneously with high sensitivity and precision.
The Prosigna Assay will be available for diagnostic use when ordered by a physician in the U.S. The Prosigna Assay has been CE-marked and is available for use by healthcare professionals in the European Union and other countries that recognize the CE Mark and in which Prosigna is registered.
Source: Nanostring Technologies
Myriad Genetics Inc.
EndoPredict is a 2nd generation breast cancer recurrence test for highly accurate assessment of 10-year risk of distant recurrence. Both gene expression with clinicopathological features are integrated into the EndoPredict test result to provide improved prognostic performance.
EndoPredict is appropriate for women with:
- early-stage invasive breast cancer (ref Filipits)
- ER+, HER2− receptor status (ref Filipits)
- node-negative (N0) and node-positive (N1)